Acetylcholinesterase inhibitors considerably affect the salivary microbiome in patients with Alzheimer’s disease

IF 4.6 2区综合性期刊 Q1 MULTIDISCIPLINARY SCIENCES

iScience Pub Date : 2025-05-06 DOI:10.1016/j.isci.2025.112593

Daisuke Hisamatsu , Hiroaki Masuoka , Haruka Takeshige-Amano , Rina Kurokawa , Yusuke Ogata , Wataru Suda , Taku Hatano , Daisuke Asaoka , Yo Mabuchi , Yuna Naraoka , Nobuhiro Sato , Takashi Asada , Nobutaka Hattori , Masahira Hattori , Chihiro Akazawa

{"title":"Acetylcholinesterase inhibitors considerably affect the salivary microbiome in patients with Alzheimer’s disease","authors":"Daisuke Hisamatsu , Hiroaki Masuoka , Haruka Takeshige-Amano , Rina Kurokawa , Yusuke Ogata , Wataru Suda , Taku Hatano , Daisuke Asaoka , Yo Mabuchi , Yuna Naraoka , Nobuhiro Sato , Takashi Asada , Nobutaka Hattori , Masahira Hattori , Chihiro Akazawa","doi":"10.1016/j.isci.2025.112593","DOIUrl":null,"url":null,"abstract":"<div><div>Microbiome alterations are reportedly linked to systemic disease progression and medication. However, the effects of central nervous system drugs on the microbiome of patients with neurodegenerative diseases, such as Alzheimer’s or Parkinson’s disease, are poorly understood. Here, we comprehensively analyzed the effects of medication on the salivary and gut microbiomes of patients with Alzheimer’s or Parkinson’s disease. Comparative analyses of the effects of disease severity and drug use revealed that anti-dementia (DE) drugs, particularly acetylcholinesterase inhibitors, had a greater effect on compositional changes in the salivary microbiome than on those in the gut microbiome. Multivariate analyses incorporating anti-DE drug use showed that microbial signatures may serve as promising disease biomarkers, enabling the development of more precise predictors of cognitive function. Our findings will facilitate the advancement of diagnostic tools leveraging the salivary microbiome.</div></div>","PeriodicalId":342,"journal":{"name":"iScience","volume":"28 6","pages":"Article 112593"},"PeriodicalIF":4.6000,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"iScience","FirstCategoryId":"103","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2589004225008545","RegionNum":2,"RegionCategory":"综合性期刊","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MULTIDISCIPLINARY SCIENCES","Score":null,"Total":0}

引用次数: 0

Abstract

Microbiome alterations are reportedly linked to systemic disease progression and medication. However, the effects of central nervous system drugs on the microbiome of patients with neurodegenerative diseases, such as Alzheimer’s or Parkinson’s disease, are poorly understood. Here, we comprehensively analyzed the effects of medication on the salivary and gut microbiomes of patients with Alzheimer’s or Parkinson’s disease. Comparative analyses of the effects of disease severity and drug use revealed that anti-dementia (DE) drugs, particularly acetylcholinesterase inhibitors, had a greater effect on compositional changes in the salivary microbiome than on those in the gut microbiome. Multivariate analyses incorporating anti-DE drug use showed that microbial signatures may serve as promising disease biomarkers, enabling the development of more precise predictors of cognitive function. Our findings will facilitate the advancement of diagnostic tools leveraging the salivary microbiome.

查看原文本刊更多论文

乙酰胆碱酯酶抑制剂显著影响阿尔茨海默病患者唾液微生物组

据报道，微生物组的改变与全身性疾病的进展和药物治疗有关。然而，中枢神经系统药物对神经退行性疾病（如阿尔茨海默病或帕金森病）患者微生物组的影响尚不清楚。在这里，我们综合分析了药物对阿尔茨海默病或帕金森病患者唾液和肠道微生物组的影响。对疾病严重程度和药物使用影响的比较分析显示，抗痴呆（DE）药物，特别是乙酰胆碱酯酶抑制剂，对唾液微生物组的组成变化的影响大于对肠道微生物组的影响。结合抗de药物使用的多变量分析表明，微生物特征可能作为有希望的疾病生物标志物，能够开发更精确的认知功能预测因子。我们的发现将促进利用唾液微生物组的诊断工具的进步。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

iScience Multidisciplinary-Multidisciplinary

CiteScore

7.20

自引率

1.70%

发文量

1972

审稿时长

6 weeks

期刊介绍： Science has many big remaining questions. To address them, we will need to work collaboratively and across disciplines. The goal of iScience is to help fuel that type of interdisciplinary thinking. iScience is a new open-access journal from Cell Press that provides a platform for original research in the life, physical, and earth sciences. The primary criterion for publication in iScience is a significant contribution to a relevant field combined with robust results and underlying methodology. The advances appearing in iScience include both fundamental and applied investigations across this interdisciplinary range of topic areas. To support transparency in scientific investigation, we are happy to consider replication studies and papers that describe negative results. We know you want your work to be published quickly and to be widely visible within your community and beyond. With the strong international reputation of Cell Press behind it, publication in iScience will help your work garner the attention and recognition it merits. Like all Cell Press journals, iScience prioritizes rapid publication. Our editorial team pays special attention to high-quality author service and to efficient, clear-cut decisions based on the information available within the manuscript. iScience taps into the expertise across Cell Press journals and selected partners to inform our editorial decisions and help publish your science in a timely and seamless way.